摘要
目的观察贝伐单抗联合胸腔灌注化疗治疗非小细胞肺癌(NSCLC)合并恶性胸腔积液的临床疗效。方法选取2016年1月—2020年12月福建省福鼎市医院收治的NSCLC合并恶性胸腔积液患者70例,采用随机数字表法分为观察组和对照组,每组35例。对照组患者采用常规胸腔灌注化疗治疗,观察组在对照组基础上采用贝伐单抗治疗。比较2组患者治疗效果,治疗前后胸腔积液白介素-6(IL-6)、白介素-8(IL-8)及血管内皮生长因子(VEGF)水平,不良反应。结果观察组患者肿瘤治疗总控制率为77.14%,高于对照组的51.43%,差异有统计学意义(χ^(2)=5.040,P=0.025);观察组患者胸腔积液治疗总有效率为71.43%,高于对照组的42.86%,差异有统计学意义(χ^(2)=5.833,P=0.016)。治疗后,2组患者胸腔积液IL-6、IL-8及VEGF水平均低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.01)。观察组患者骨髓抑制、恶心呕吐、高血压等不良反应的发生率基本与对照组相当,差异无统计学意义(P>0.05)。结论贝伐单抗联合胸腔灌注治疗NSCLC合并胸腔恶性积液的疗效较好,可有效减少胸腔积液,并降低积液中IL-6、IL-8和VEGF水平。
Objective To observe the clinical efficacy of bevacizumab combined with pleural infusion chemotherapy in the treatment of non-small cell lung cancer(NSCLC)complicated with malignant pleural effusion.Methods 70 patients with NSCLC complicated with malignant pleural effusion admitted to Fuding Hospital of Fujian Province from January 2016 to December 2020 were selected,and they were divided into observation group and control group by random number table method,35 cases in each group.The control group was treated with conventional thoracic perfusion chemotherapy,and the observation group was treated with bevacizumab on the basis of the control group.The treatment effect,levels of interleukin-6(IL-6),interleukin-8(IL-8)and vascular endothelial growth factor(VEGF)in pleural effusion before and after treatment,and adverse reactions were compared between the two groups.Results Overall control rate of tumor treatment of observation group was 77.14%,higher than 15.43%of control group,the difference was statistically significant(χ^(2)=5.040,P=0.025).Total effective rate of pleural effusion treatment of observation group was 71.43%higher than 42.86%of control group,the difference was statistically significant(χ^(2)=5.833,P=0.016).After treatment,the levels of IL-6,IL-8 and VEGF in pleural effusion of two groups were lower than before the treatment,and observation group were lower than those of control group,the difference were statistically significant(P<0.01).There were no significant difference in the incidence of adverse reactions such as bone marrow suppression,nausea and vomiting,hypertension between the two groups(P>0.05).Conclusion Bevacizumab combined with pleural perfusion is effective in the treatment of NSCLC complicated with pleural malignant effusion,which can effectively reduce pleural effusion,and reduce the levels of IL-6,IL-8 and VEGF in pleural effusion.
作者
陈鹏涛
艾岩
CHEN Pengtao;AI Yan(Department of Oncology,Fuding Hospital of Fujian Province,Fuding 350052,China)
出处
《临床合理用药杂志》
2022年第34期17-19,23,共4页
Chinese Journal of Clinical Rational Drug Use
关键词
非小细胞肺癌
恶性胸腔积液
贝伐单抗
胸腔灌注化疗
炎性因子
Non-small cell lung cancer
Malignant pleural effusion
Bevacizumab
Thoracic perfusion chemotherapy
Inflammatory cytokines
